Form 4: Fate Therapeutics Director Robert Epstein Receives Annual Stock Option Grant

Fate Therapeutics, Inc. Director Robert S. Epstein was granted 55,000 stock options at an exercise price of $1.32 per share, vesting over one year, as part of the company's non-employee director compensation policy.

Summary

• Robert S. Epstein, a Director of Fate Therapeutics, Inc. (FATE), was granted 55,000 stock options on May 29, 2025.
• The exercise price for these options is $1.32 per share.
• The options will vest and become exercisable on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.
• Vesting is contingent upon Mr. Epstein's continued service on the Issuer's Board of Directors.
• The options are set to expire on May 29, 2035.
• This grant is consistent with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, which provides for annual equity grants to non-employee directors.
• Mr. Epstein also executed a Limited Power of Attorney, effective May 29, 2025, authorizing specific individuals to file SEC forms on his behalf.

Sentiment

Score: 7

Explanation: The document reports a routine, expected compensation event for a director, reflecting standard corporate governance practices. It is neutral to slightly positive as it indicates continued director engagement and adherence to compensation policies.

Positives

• The grant of stock options aligns with the company's established Amended and Restated Non-Employee Director Compensation Policy, indicating a standard and transparent compensation practice for directors.
• The vesting schedule encourages continued service and aligns the director's interests with long-term shareholder value.
• The Power of Attorney streamlines the process for timely and accurate SEC filings for the director, ensuring compliance with reporting obligations.

Future Outlook

The vesting schedule of the options, tied to continued service until May 29, 2026, or the 2026 Annual Meeting of Stockholders, indicates an expectation of continued board stability and strategic oversight from Mr. Epstein.

Management Comments

• "This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."
• "The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."

Industry Context

This is a routine director compensation disclosure common across all industries, including biotechnology. It reflects standard practices for aligning director incentives with company performance through equity grants, which is a widely adopted method for attracting and retaining experienced board members in competitive sectors.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, similar to companies like Gilead Sciences, Amgen, or Biogen, which use equity compensation to attract and retain experienced board members.
• The vesting schedule, typically over one year or tied to the next annual meeting, is standard for annual director equity grants, ensuring continued commitment and alignment with long-term company performance.
• The exercise price being set at a specific value ($1.32) is typical for option grants, reflecting a valuation at the time of grant, consistent with market practices for director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns director incentives with shareholder interests through equity ownership, potentially encouraging long-term value creation. It also reflects standard governance and compensation practices.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued service of Robert S. Epstein on the Board of Directors of Fate Therapeutics, Inc.
• Vesting of the granted stock options on the earlier of May 29, 2026, or the 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

Fate Therapeutics, FATE, Robert S. Epstein, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Beneficial Ownership, Biotechnology, Pharmaceuticals, Corporate Governance